Rapid optimization and prototyping for therapeutic antibody-like molecules.

ABSTRACT: Multispecific antibody-like molecules have the potential to advance the standard-of-care in many human diseases. The design of therapeutic molecules in this class, however, has proven to be difficult and, despite significant successes in preclinical research, only one trivalent antibody, catumaxomab, has demonstrated clinical utility. The challenge originates from the complexity of the design space where multiple parameters such as affinity, avidity, effector functions, and pharmaceutical properties need to be engineered in concurrent fashion to achieve the desired therapeutic efficacy. Here, we present a rapid prototyping approach that allows us to successfully optimize these parameters within one campaign cycle that includes modular design, yeast display of structure focused antibody lib

SUBMITTER: Xu L 

PROVIDER: S-EPMC3893234 | biostudies-literature | 2013 Mar-Apr

REPOSITORIES: biostudies-literature